Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 13 | 2017 | 137 | 1.170 |
Why?
|
| Salivary Gland Neoplasms | 3 | 2017 | 13 | 1.100 |
Why?
|
| Thyroidectomy | 3 | 2020 | 20 | 1.020 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2017 | 7 | 1.010 |
Why?
|
| Hypocalcemia | 2 | 2020 | 14 | 0.980 |
Why?
|
| Parathyroidectomy | 2 | 2020 | 21 | 0.730 |
Why?
|
| Calcium | 3 | 2020 | 339 | 0.710 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 8 | 0.620 |
Why?
|
| Temporal Bone | 1 | 2019 | 19 | 0.610 |
Why?
|
| Ossification, Heterotopic | 1 | 2019 | 21 | 0.600 |
Why?
|
| Postoperative Complications | 3 | 2020 | 823 | 0.570 |
Why?
|
| Receptors, Chemokine | 1 | 2016 | 11 | 0.490 |
Why?
|
| Chemokines | 1 | 2016 | 34 | 0.490 |
Why?
|
| Esophageal Stenosis | 3 | 2011 | 6 | 0.480 |
Why?
|
| Thyroid Neoplasms | 2 | 2008 | 34 | 0.480 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2016 | 157 | 0.450 |
Why?
|
| MicroRNAs | 1 | 2017 | 181 | 0.440 |
Why?
|
| Parathyroid Hormone | 2 | 2014 | 46 | 0.440 |
Why?
|
| Parathyroid Neoplasms | 1 | 2014 | 7 | 0.410 |
Why?
|
| Hypercalcemia | 1 | 2014 | 12 | 0.410 |
Why?
|
| Adenoma | 1 | 2014 | 35 | 0.400 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2014 | 17 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2006 | 443 | 0.380 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 423 | 0.370 |
Why?
|
| Early Diagnosis | 1 | 2011 | 57 | 0.350 |
Why?
|
| Plicamycin | 1 | 2011 | 1 | 0.340 |
Why?
|
| Burns, Chemical | 1 | 2011 | 7 | 0.340 |
Why?
|
| Drug-Eluting Stents | 1 | 2011 | 14 | 0.340 |
Why?
|
| Female | 22 | 2020 | 19947 | 0.330 |
Why?
|
| Middle Aged | 18 | 2020 | 11853 | 0.330 |
Why?
|
| Aged | 16 | 2020 | 10265 | 0.320 |
Why?
|
| Collagen | 1 | 2011 | 229 | 0.310 |
Why?
|
| Male | 19 | 2020 | 19443 | 0.310 |
Why?
|
| Humans | 28 | 2020 | 32284 | 0.310 |
Why?
|
| Treatment Outcome | 10 | 2019 | 3416 | 0.300 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2008 | 1 | 0.280 |
Why?
|
| Eosinophilia | 1 | 2008 | 11 | 0.270 |
Why?
|
| Smoking | 3 | 2016 | 505 | 0.260 |
Why?
|
| Salivary Glands | 3 | 2017 | 14 | 0.250 |
Why?
|
| Adult | 13 | 2020 | 9259 | 0.240 |
Why?
|
| Submandibular Gland | 1 | 2005 | 4 | 0.230 |
Why?
|
| Hypopharynx | 1 | 2004 | 2 | 0.220 |
Why?
|
| Gastroscopy | 1 | 2004 | 8 | 0.220 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 729 | 0.220 |
Why?
|
| Retrospective Studies | 7 | 2020 | 3628 | 0.210 |
Why?
|
| Laryngoscopy | 1 | 2004 | 38 | 0.210 |
Why?
|
| Length of Stay | 3 | 2019 | 321 | 0.210 |
Why?
|
| Ventilator Weaning | 1 | 2004 | 4 | 0.210 |
Why?
|
| Carcinoma | 1 | 2005 | 92 | 0.210 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 33 | 0.210 |
Why?
|
| Clinical Protocols | 1 | 2004 | 77 | 0.210 |
Why?
|
| Time Factors | 3 | 2019 | 2205 | 0.200 |
Why?
|
| Cross Infection | 1 | 2004 | 57 | 0.200 |
Why?
|
| Neck Dissection | 4 | 2008 | 11 | 0.200 |
Why?
|
| Respiration, Artificial | 1 | 2004 | 98 | 0.200 |
Why?
|
| Combined Modality Therapy | 8 | 2014 | 555 | 0.190 |
Why?
|
| Taxoids | 5 | 2006 | 50 | 0.180 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 545 | 0.170 |
Why?
|
| Blood Loss, Surgical | 1 | 2019 | 50 | 0.150 |
Why?
|
| Paclitaxel | 3 | 2005 | 57 | 0.150 |
Why?
|
| Vitamin D | 1 | 2020 | 186 | 0.140 |
Why?
|
| Prognosis | 3 | 2020 | 1534 | 0.140 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2017 | 8 | 0.130 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2017 | 9 | 0.130 |
Why?
|
| Micronutrients | 1 | 2017 | 20 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 124 | 0.120 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 3902 | 0.120 |
Why?
|
| Plant Extracts | 1 | 2017 | 61 | 0.120 |
Why?
|
| Gene Expression | 1 | 2017 | 346 | 0.120 |
Why?
|
| Cesium Radioisotopes | 1 | 2015 | 4 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 180 | 0.120 |
Why?
|
| Gamma Rays | 1 | 2015 | 25 | 0.120 |
Why?
|
| Laryngeal Muscles | 1 | 2015 | 17 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 38 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 222 | 0.110 |
Why?
|
| Muscle Proteins | 1 | 2015 | 63 | 0.110 |
Why?
|
| Self Disclosure | 1 | 2015 | 21 | 0.110 |
Why?
|
| Muscular Atrophy | 1 | 2015 | 74 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2006 | 86 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 258 | 0.110 |
Why?
|
| Mucositis | 1 | 2014 | 10 | 0.110 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 12 | 0.110 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2014 | 23 | 0.100 |
Why?
|
| Rare Diseases | 1 | 2014 | 18 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 95 | 0.100 |
Why?
|
| Salivary Glands, Minor | 1 | 2013 | 10 | 0.100 |
Why?
|
| Reference Values | 2 | 2011 | 238 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2011 | 2240 | 0.090 |
Why?
|
| Thyroid Diseases | 1 | 2011 | 6 | 0.090 |
Why?
|
| ROC Curve | 1 | 2011 | 169 | 0.080 |
Why?
|
| Mucous Membrane | 1 | 2011 | 27 | 0.080 |
Why?
|
| Carboplatin | 3 | 2006 | 42 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2006 | 187 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 853 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 504 | 0.080 |
Why?
|
| Administration, Topical | 1 | 2011 | 142 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 298 | 0.080 |
Why?
|
| Random Allocation | 1 | 2011 | 247 | 0.080 |
Why?
|
| Dilatation | 1 | 2010 | 8 | 0.080 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 461 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 883 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 897 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2014 | 1425 | 0.070 |
Why?
|
| Sclerosis | 1 | 2008 | 9 | 0.070 |
Why?
|
| Cisplatin | 5 | 2006 | 78 | 0.070 |
Why?
|
| Fluorouracil | 5 | 2006 | 79 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 1083 | 0.060 |
Why?
|
| Tissue Culture Techniques | 1 | 2007 | 42 | 0.060 |
Why?
|
| Rats | 1 | 2011 | 1895 | 0.060 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2006 | 1 | 0.060 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2006 | 9 | 0.060 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 53 | 0.060 |
Why?
|
| Laryngeal Neoplasms | 1 | 2005 | 16 | 0.060 |
Why?
|
| Xerostomia | 1 | 2005 | 28 | 0.060 |
Why?
|
| Animals | 3 | 2015 | 8199 | 0.060 |
Why?
|
| Cotinine | 2 | 2015 | 40 | 0.060 |
Why?
|
| Pharyngeal Diseases | 1 | 2004 | 10 | 0.050 |
Why?
|
| Nasal Bone | 1 | 2004 | 5 | 0.050 |
Why?
|
| Fibrosis | 1 | 2005 | 126 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2004 | 45 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 1479 | 0.050 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2004 | 44 | 0.050 |
Why?
|
| Incidence | 2 | 2006 | 1241 | 0.050 |
Why?
|
| Infection Control Practitioners | 1 | 2004 | 1 | 0.050 |
Why?
|
| Respiratory Therapy | 1 | 2004 | 2 | 0.050 |
Why?
|
| Fetus | 1 | 2004 | 76 | 0.050 |
Why?
|
| Infection Control | 1 | 2004 | 26 | 0.050 |
Why?
|
| Injury Severity Score | 1 | 2004 | 110 | 0.050 |
Why?
|
| Age Distribution | 1 | 2004 | 194 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2004 | 121 | 0.050 |
Why?
|
| Critical Care | 1 | 2004 | 108 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2004 | 197 | 0.050 |
Why?
|
| Tissue Engineering | 2 | 2007 | 695 | 0.050 |
Why?
|
| Risk Factors | 2 | 2015 | 3934 | 0.050 |
Why?
|
| Inflammation | 1 | 2005 | 506 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2015 | 299 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2015 | 2316 | 0.040 |
Why?
|
| Survival Rate | 3 | 2006 | 893 | 0.040 |
Why?
|
| Powders | 1 | 2017 | 8 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2017 | 32 | 0.030 |
Why?
|
| Phytotherapy | 1 | 2017 | 36 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 32 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 101 | 0.030 |
Why?
|
| Antioxidants | 1 | 2017 | 122 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 47 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2015 | 22 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 565 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2017 | 188 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2006 | 168 | 0.030 |
Why?
|
| Mice | 2 | 2015 | 2571 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2007 | 839 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2014 | 92 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 324 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 792 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 757 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2014 | 205 | 0.020 |
Why?
|
| Eating | 1 | 2010 | 77 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 595 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 907 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2007 | 10 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2007 | 37 | 0.020 |
Why?
|
| Remission Induction | 1 | 2006 | 92 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 107 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 34 | 0.010 |
Why?
|
| Laryngectomy | 1 | 2005 | 3 | 0.010 |
Why?
|
| Aquaporin 5 | 1 | 2005 | 4 | 0.010 |
Why?
|
| Biodegradation, Environmental | 1 | 2005 | 4 | 0.010 |
Why?
|
| Aquaporins | 1 | 2005 | 5 | 0.010 |
Why?
|
| alpha-Amylases | 1 | 2005 | 4 | 0.010 |
Why?
|
| Keratins | 1 | 2005 | 39 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 55 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2004 | 11 | 0.010 |
Why?
|
| Pregnancy Trimester, First | 1 | 2004 | 8 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2007 | 461 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2004 | 23 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2005 | 135 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 246 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 125 | 0.010 |
Why?
|
| Disease Progression | 1 | 2006 | 591 | 0.010 |
Why?
|
| Diet | 1 | 2006 | 383 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 308 | 0.010 |
Why?
|
| Organoids | 1 | 2005 | 99 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 243 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 622 | 0.010 |
Why?
|
| Leucovorin | 1 | 2003 | 19 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2003 | 23 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2003 | 10 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2003 | 14 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 381 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 165 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 276 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 1840 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 477 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 961 | 0.010 |
Why?
|
| Quality of Life | 1 | 2006 | 964 | 0.010 |
Why?
|